NCONTACT VISITRAX GUIDED COAGULATION SYSTEM KIT, MODELS CSK-212 AND CSK-515
K071819 · Ncontact Surgical, Inc. · OCL · Jul 26, 2007 · General, Plastic Surgery
Device Facts
Record ID
K071819
Device Name
NCONTACT VISITRAX GUIDED COAGULATION SYSTEM KIT, MODELS CSK-212 AND CSK-515
Applicant
Ncontact Surgical, Inc.
Product Code
OCL · General, Plastic Surgery
Decision Date
Jul 26, 2007
Decision
SESE
Submission Type
Special
Regulation
21 CFR 878.4400
Device Class
Class 2
Attributes
Therapeutic
Intended Use
The nContact Coagulation System (VisiTrax™) is intended for the coagulation of cardiac tissue using Radiofrequency (RF) energy.
Device Story
The nContact Guided Coagulation System (VisiTrax) is a sterile, single-use, disposable electrosurgical device used to coagulate cardiac tissue. It features a flexible, cooled electrode with a suction stabilizer. The device transmits radiofrequency (RF) energy from a non-sterile, reusable electrosurgical generator via a sterile instrument cable. It is intended for use by clinicians in a surgical setting. The system functions by delivering RF energy to target tissue to achieve coagulation. The device modifications include minor material and design changes while maintaining the same principle of operation as the predicate. The system is provided in 2cm and 5cm electrode sizes.
Clinical Evidence
Bench testing only. Performance bench tests were conducted to ensure the device performed as intended and met design specifications.
Technological Characteristics
Electrosurgical coagulation device; transmits RF energy from an external generator. Components: sterile single-use disposable coagulation electrode (2cm/5cm), sterile instrument cable, and non-sterile reusable electrosurgical generator. Features suction stabilizer. Materials modified from predicate. No software/algorithm described.
Indications for Use
Indicated for the coagulation of cardiac tissue using radiofrequency (RF) energy. Prescription use only.
Regulatory Classification
Identification
An electrosurgical cutting and coagulation device and accessories is a device intended to remove tissue and control bleeding by use of high-frequency electrical current.
Predicate Devices
nContact Coagulation System (CSK) Model numbers: CSK-100; CSK-200; CSK-500 (K063012)
Related Devices
K063012 — NCONTACT COAGULATION SYSTEM KIT, MODEL CSK · Ncontact Surgical, Inc. · Dec 1, 2006
K090202 — NUMERIS GUIDED COAGULATION SYSTEM WITH VISITRAX, MODELS CSK-121, -122, -123 AND -125 · Ncontact Surgical, Inc. · Feb 17, 2009
K062539 — NCONTACT COAGULATION SYSTEM KIT · Ncontact Surgical, Inc. · Dec 1, 2006
K082203 — NUMERIS COAGULATION SYSTEM WITH VISITRAX, MODEL(S) CSK-021;CSK-022; CSK-023; CSK-025 · Ncontact Surgical, Inc. · Dec 30, 2008
K120857 — EPI-SENSE GUIDED COAGULATION DEVICE WITH VISITRAX · Ncontact Surgical, Inc. · Nov 13, 2012
Submission Summary (Full Text)
{0}------------------------------------------------
nContact Surgical, Inc. Coagulation System Device Modification
Special 510k Notification
# KO71819
JUL 26 2007
Special 510(k) Summary:
| Special 510(k) Summary: | |
|---------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|
| Page 1 of 2 | |
| Application Date: | July 2, 2007 |
| Sponsor: | nContact Surgical, Inc.<br>new address: |
| | 1001 Aviation Parkway, Suite 400,<br>Morrisville, NC 27560 |
| | formerly at:<br>2880 Slater Road, Suite 103,<br>Morrisville, NC 27560 |
| Establishment Registration<br>Number: | 3006142617 |
| Correspondent: | Jane Ricupero<br>Director of Regulatory & Quality<br>1001 Aviation Parkway, Suite 400,<br>Morrisville, NC 27560 |
| Contact Numbers: | Phone: 919 466-9810 x3013<br>Fax: 919 466-9811<br>E-mail: jane@ncontact.us |
| Device Proprietary Name: | nContact Guided Coagulation System<br>or VisiTrax <sup>TM</sup> Guided Coagulation<br>System<br>Model numbers: CSK-212; CSK-515 |
| Device Common Name: | Electrosurgical device and<br>accessories |
| Device Classification: | 21 CFR 878.4400 |
| Product Code: | GEI |
| Classification Name: | Electrosurgical cutting and<br>coagulation device and accessories |
| Accessory Classification: Cannula | 21 CFR 878.4800 (Manual surgical<br>instrument for general use) |
| Accessory Product Code: Cannula | GEA (Class I exempt) |
| Predicate Device | 1. nContact Surgical Inc.,<br>nContact Coagulation System<br>(CSK) Model numbers: CSK-100;<br>CSK-200; CSK-500 |
| Legally marketed unmodified<br>device 510k number | K063012 cleared Dec. 1/06 |
Section 5 – Summary
Page 5-1 of 5-2
{1}------------------------------------------------
page 2 of (2)
## Device Description:
The nContact Guided Coagulation System (VisiTrax) consists of a sterile, single-use, disposable coagulation electrode device (2cm & 5cm sizes provided) intended to be used to coagulate cardiac tissue. The flexible, cooled electrode device, with a suction stabilizer feature, transmits radiofrequency (RF) energy from an Electrosurgical Generator (non-sterile, re-useable) connected through an Instrument Cable (sterile). The functionality of this System is the same as the cleared predicate system.
#### Indications for Use:
The nContact Guided Coagulation System (VisiTrax) is intended for the coagulation of cardiac tissue using radiofrequency (RF) energy. The indications for use of this System are the same as the cleared predicate system.
#### Technological Characteristics:
The modified nContact Coagulation Device has minor material changes and minor design modifications with the main technological characteristics of transmitting RF energy from an electrosurgical generator connected by an instrument cable to a coagulation electrode remaining identical to the predicate device.
## Performance Data:
Performance bench tests were executed to ensure that the nContact Guided Coagulation System (VisiTrax) performed as intended and met design specifications.
## Substantial Equivalence Conclusion:
This special 510(k) proposes that the material and design modifications for the nContact Guided Coagulation System (VisiTrax) may be considered substantially equivalent to the legally marketed unmodified nContact Coagulation System (previously cleared under K063012 on Dec. 1, 2006) based on the results of design verification and validation. The indications for use, principle of operation, technology, performance specifications (as reverified through design controls), labeling and sterilization parameters are not substantial changes or modifications, and do not significantly affect the safety or efficacy of the devices.
We believe that the nContact Guided Coagulation System (VisiTrax) is substantially equivalent to the unmodified predicate device.
Section 5 - Summary Page 5-2 of 5-2
{2}------------------------------------------------
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with its wings spread, and the words "DEPARTMENT OF HEALTH & HUMAN SERVICES . USA" are arranged in a circular pattern around the eagle. The eagle is black, and the text is also black. The background is white.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
FEB 2 1 2008
nContact Surgical, Inc. c/o Ms. Jane Ricupero Director, Regulatory and Quality 1001 Aviation Parkway, Sutie 400 Morrisville, NC 27560
Re: K071819
Trade/Device Name: Contact Guided Coagulation System (VisiTrax™) Regulation Number: 21 CFR 878.4400 Regulation Name: Electrosurgical cutting and coagulation device and accessories Regulatory Class: II (two) Product Code: OCL Dated: July 2, 2007 Received: July 3, 2007
Dear Ms. Ricupero:
This letter corrects our substantially equivalent letter of July 26, 2007.
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{3}------------------------------------------------
Page 2 - Ms. Jane Ricupero
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to continue marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely yours,
elgmee
\$\theta\$
Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
## Indications for Use
510(k) Number (if known): __ K_OZI 81 9
Device Name: nContact Guided Coagulation System (VisiTrax™)
Indications for Use: The nContact Coagulation System (VisiTrax™) is intended for the coagulation of cardiac tissue using Radiofrequency (RF) energy.
Mark M. Milken
(Division Sign.Off (Division of General, Restorative, and Neurological Devices
09/8/9 510(k) Number_
Prescription Use X (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
# Concurrence of CDRH, Office of Device Evaluation (ODE)
Section 4 - Indications for Use Statement Page 4-1 of 4-1
Panel 1
/
Sort by
Ready
Predicate graph will load when search results are available.
Embedding visualization will load when search results are available.
PDF viewer will load when search results are available.
Loading panels...
Select an item from Submissions
Click any panel, subpart, regulation, product code, or device to see details here.
Section Matches
Results will appear here.
Product Code Matches
Results will appear here.
Special Control Matches
Results will appear here.
Loading collections...
Loading
My Alerts
You will receive email notifications based on the filters and frequency you set for each alert.